<DOC>
	<DOCNO>NCT00850993</DOCNO>
	<brief_summary>The purpose study determine experimental drug , stannsoporfin , safe effective treatment hyperbilirubinemia hemolyzing neonate .</brief_summary>
	<brief_title>A Safety Efficacy Trial Stannsoporfin Neonates With Hyperbilirubinemia</brief_title>
	<detailed_description />
	<mesh_term>Hyperbilirubinemia</mesh_term>
	<mesh_term>Hyperbilirubinemia , Neonatal</mesh_term>
	<mesh_term>Tin mesoporphyrin</mesh_term>
	<criteria>Term late preterm subject Risk factor hemolytic disease include ABO blood type incompatibility Rh incompatibility ( antiC , c , D , E , e , G6PD deficiency A minimum birth weight 2500 g ( 5.5 lb ) Enrollment within 2 mg/dL Total Serum Bilirubin ( TSB ) threshold PhotoTherapy ( PT ) per AAP Guidelines 12 hour age within 3 mg/dL threshold PhotoTherapy ( PT ) &gt; 12 48 hour age , inclusive Randomization treatment take place infant within 1 mg/dl threshold PhotoTherapy ( PT ) per American Association Pediatrics ( AAP ) Guidelines 12 hour age within 2 mg/dL threshold PT &gt; 12 48 hour age , inclusive Treatment need treatment neonate medication may prolong QT interval , family history Long QT syndrome family history Sudden Infant Death Syndrome Risk factor porphyrias , include family history Apgar score â‰¤6 age 5 minute Significant congenital anomaly infection Cardiorespiratory distress Any abnormal auditory ophthalmologic finding Any excess risk require surgery exposure operate room light foreseeable future Clinically significant abnormality screen laboratory evaluation Use photosensitizing drug agent Use intravenous immunoglobulin ( IVIG ) albumins Other serious morbid condition , eg , pulmonary disease , cardiovascular disease</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>48 Hours</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Hemolysis</keyword>
</DOC>